Cleary Gottlieb Steen & Hamilton (Washington)

Kenneth Reinker

Cleary Gottlieb Steen & Hamilton (Washington)
Lawyer (Associate)

Kenneth S. Reinker’s practice focuses on all aspects of antitrust law, including litigation, government investigations, and merger review.

Auteurs associés

Cleary Gottlieb Steen & Hamilton (Milano)
Cleary Gottlieb Steen & Hamilton (Hong Kong)
Cleary Gottlieb Steen & Hamilton (London)
Cleary Gottlieb Steen & Hamilton (Washington)
Cleary Gottlieb Steen & Hamilton (Brussels)

Articles

725 Bulletin

Bruce Hoffman, Kenneth Reinker The US Supreme Court holds that Section 13(b) of the FTC Act does not authorize the Federal Trade Commission to seek, or a court to award, equitable monetary relief such as restitution or disgorgement (AMG Capital Management)

161

On April 22, 2021, the Supreme Court unanimously held that section 13(b) of the Federal Trade Commission Act - which authorizes “a permanent injunction”- does not authorize the Federal Trade Commission to seek, or a court to award, equitable monetary relief such as restitution or disgorgement. (...)

Kenneth Reinker, Bruce Hoffman, Kathleen W. Bradish, George S. Cary The US Court of Appeals for the Fifth Circuit upholds the FTC’s decision in the first fully litigated reverse payment decision against generic pharmaceutical companies (Endo / Impax)

332

On April 13, the U.S. Court of Appeals for the Fifth Circuit affirmed the Federal Trade Commission’s decision that Impax Laboratories entered an anticompetitive “reverse payment” settlement with Endo Pharmaceuticals. This case was the FTC’s first fully litigated reverse payment case since the (...)

Kenneth Reinker, Bruce Hoffman, Kathleen W. Bradish, George S. Cary The US Court of Appeals for the Fifth Circuit upholds the FTC’s decision that two pharmaceutical companies entered an anticompetitive reverse payment settlement (Endo / Impax)

171

On April 13, the U.S. Court of Appeals for the Fifth Circuit affirmed the Federal Trade Commission’s decision that Impax Laboratories entered an anticompetitive “reverse payment” settlement with Endo Pharmaceuticals. This case was the FTC’s first fully litigated reverse payment case since the (...)

Leah Brannon, Brian R. Byrne, Jeremy J. Calsyn, George S. Cary, Alexis Collins, Daniel P. Culley, Elaine Ewing, David I. Gelfand, Bruce Hoffman, Mark W. Nelson, Kenneth Reinker The US FTC issues commentary on vertical merger enforcement explaining the approach to assessing the competitive effects of vertical mergers

61

On December 22, 2020, the US Federal Trade Commission (the “FTC”) issued a Commentary on Vertical Merger Enforcement. This follows the recent issuance of revised Vertical Merger Guidelines published jointly by the FTC and Department of Justice (the “Agencies”) on June 30, 2020. While the Guidelines (...)

Envoyer un message